5-Thio-D-glucopyranose | 686298-90-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻烷
• 英文名称: 5-Thio-D-glucopyranose
• 英文别名: 6-(hydroxymethyl)thiane-2,3,4,5-tetrol
• CAS: 686298-90-8
• 化学式: C₆H₁₂O₅S
• 分子量: 196.224
• InChiKey: KNWYARBAEIMVMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  126
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• [EN] RAPAMYCIN CARBOHYDRATE DERIVATIVES<br/>[FR] DERIVES DE RAPAMYCINE CARBOHYDRATE
  申请人：ISOTECHNIKA INTERNAT INC

  公开号：WO2004101583A1

  公开（公告）日：2004-11-25

  This invention provides modified rapamycins that have specific monosaccharide(s), oligosaccharide(s), pseudosugar(s) or derivatives thereof attached through a linker to create rapamycin carbohydrate derivatives having enhanced pharmacokinetic and/or pharmacodynamic profiles. For example, administration of the rapamycin carbohydrate derivative results in altered pharmacokinetic profiles and reduced toxicities. Thus, the present invention provides compounds with characteristics that are distinct from other drugs in its class such as rapamycin.

  这项发明提供了经过改良的雷帕霉素，其具有通过连接剂连接的特定单糖，寡糖，伪糖或其衍生物，从而创造出具有增强药代动力学和/或药效动力学特性的雷帕霉素糖衍生物。例如，给予雷帕霉素糖衍生物的治疗导致了改变的药代动力学特性和降低的毒性。因此，本发明提供了具有与其他同类药物（如雷帕霉素）不同特性的化合物。
• Modulators of Hypoxia Inducible Factor-1 and Related Uses
  申请人：Gardiner Gregory

  公开号：US20090023666A1

  公开（公告）日：2009-01-22

  The invention features compounds of formulas I or II: and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds.

  这项发明涉及公式I或II的化合物：以及这些化合物的药用盐和前药，以及使用这些化合物调节局部和全身缺氧事件效应的方法。
• Novel SGLT inhibitors
  申请人：Nomura Sumihiro

  公开号：US20080027014A1

  公开（公告）日：2008-01-31

  Novel compounds of formula (A) or a pharmaceutically acceptable salt thereof: wherein symbols are as defined in claims, which are useful as SGLT inhibitors and for treatment of diabetes and related diseases.

  化合物的新颖结构式（A）或其药学上可接受的盐： 其中符号如权利要求中所定义，这些化合物可用作SGLT抑制剂，用于治疗糖尿病及相关疾病。
• [EN] METHODS AND COMPOUNDS FOR INHIBITING GLYCOSYLTRANSFERASES<br/>[FR] MÉTHODES ET COMPOSÉS D'INHIBITION DES GLYCOSYLTRANSFÉRASES
  申请人：UNIV FRASER SIMON

  公开号：WO2011137528A1

  公开（公告）日：2011-11-10

  The invention provides, in part, compounds that are capable of inhibiting a glycosyltransferase, such as a uridine diphospho-N-acetylglucosamine:polypeptide β N-acetylglucosaminyltransferase, an alternative N-acetylglucosaminyltransferase, an N-acetylgalactosaminyltransferase, a fucosyltransferase, a xylotransferase or a sialyltransferase. The invention also provides methods for using the compounds.

  该发明提供了一些能够抑制糖基转移酶的化合物，例如尿苷二磷酸-N-乙酰葡糖胺：聚肽β-N-乙酰葡糖氨基转移酶，另类N-乙酰葡糖氨基转移酶，N-乙酰半乳糖氨基转移酶，富马醇转移酶，木糖转移酶或唾液酸转移酶。该发明还提供了使用这些化合物的方法。
• [EN] ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION<br/>[FR] GLYCOSIDES D'ENASIDENIB ET PROCÉDÉS DE TRAITEMENT DE MALADIES ASSOCIÉES À UN DYSFONCTIONNEMENT DE L'ISOCITRATE DÉSHYDROGÉNASE (IDH)
  申请人：DOUBLERAINBOW BIOSCIENCES INC

  公开号：WO2021188456A1

  公开（公告）日：2021-09-23

  Enasidenib glycosides and methods of making enasidenib glycosides are disclosed. Glycosyl transferases catalyze addition of one or more monosaccharides to enasidenib to yield enasidenib glycosides. Suitable monosaccharides can be in the L- or D- configuration and typically have 5, 6, or 7 carbons. Suitable monosaccharides include allose, apiose, arabinose, fructose, fucitol, fucose, galactose, galacturonate, glucose, glucuronic acid, mannose, N-acetylglucosamine, rhamnose, or xylose. Uridine diphosphate glycosyl transferases can catalyze formation of either an alpha or beta glycosidic bond.

  本文介绍了Enasidenib糖苷及其制备方法。糖基转移酶催化将一个或多个单糖添加到Enasidenib中，形成Enasidenib糖苷。适宜的单糖可以是L-或D-构型，并且通常具有5、6或7个碳。适宜的单糖包括阿洛糖、芹糖、阿拉伯糖、果糖、甘露醇、岩藻糖、半乳糖、半乳糖醛酸酯、葡萄糖、葡萄糖醛酸、甘露糖、N-乙酰葡萄糖胺、鼠李糖或木糖。尿苷二磷酸糖基转移酶可以催化α或β糖苷键的形成。